Europe Monodose Packaging Market Report, Size & Forecast 2026–2033: Clinical Unit Dose and the Accommodation Miniature Cliff
Europe's monodose packaging market is worth USD 1,337.3 million in 2025 and the single most important fact about it is that two unrelated businesses are counted inside that number. Sterile clinical unit dose — ampoules and vials blown, filled and sealed on one machine in one aseptic step — accounts for 20.00 billion packs and USD 1,100.0 million, or 82.25 per cent of the value. Accommodation miniature packaging accounts for 2.70 billion packs and USD 237.3 million, or 17.75 per cent. The market reaches USD 1,820.5 million by 2033, a 3.93 per cent value CAGR on a 4.83 per cent volume CAGR. Every point of that growth is clinical. The accommodation pool is not growing and will not be growing: Article 25 of Regulation (EU) 2025/40 prohibits single-use accommodation packaging intended for an individual booking from 1 January 2030, and Annex V entry 5 is the one entry in the list that makes no reference to plastic at all.
Three numbers carry the report. 2.70 billion packs leave the market by 2030, carrying 80.9 million litres of product and USD 237.3 million of packaging value. 4,315 million unit doses would be needed to replace that value at the clinical pack price — 21.58 per cent more clinical volume than Europe fills in a year, which is why the market shrinks in share terms even while it grows in money. And USD 0.0589 to USD 0.0550 is the movement in realised price per pack, because the pack that disappears is priced at 1.60 times the pack that replaces it. Europe handles 45.8 per cent more packs in 2033 and banks 36.1 per cent more money, and the gap between the two is the miniature.
The physical base is measured rather than assumed. Eurostat recorded 3.14 billion nights in EU tourist accommodation in 2025 across more than 32 million bed places and about 680,000 establishments, at roughly 50 per cent bed-place occupancy in hotels. At 1.9 guests per occupied room that is 1,652.6 million room-nights; at 3.4 monodose packs per room-night and 48 per cent miniature penetration, 2.70 billion packs. The clinical base comes from disclosed capacity: Unither Pharmaceuticals reports more than 5 billion doses a year across 14 blow-fill-seal lines and nine sites, and the report assigns it 25 per cent of European sterile unit-dose output, which puts Europe at 20.00 billion doses, or 44.5 doses per inhabitant.
What substitutes is not another monodose pack. A 300-millilitre refill contains ten times the product of a 30-millilitre miniature, so the substitution takes the pack count down by 90 per cent while leaving the product volume untouched. At any refill price below USD 0.88 — ten times the miniature's own pack price — the accommodation pool's packaging value falls. What arrives in its place is a capital cycle: about 32 million dispensers across roughly 16 million EU rooms, procured inside a window that closes on 31 December 2029. The value does not migrate to a different sachet. It migrates from a consumable to a fixture, and from a converter to an amenity supplier that already owns the dispenser range.
Basis of estimate. Four parameters are Pheonix constructions and are named here rather than buried: 1.9 guests per occupied room, 3.4 packs per room-night, 48 per cent miniature penetration in 2025, and a 25 per cent European share for Unither's disclosed capacity. Pack prices — USD 0.088 for a miniature, USD 0.055 for a sterile unit dose — are Pheonix constructions at constant money, held flat through 2033. Everything else is sourced: the nights, bed places, establishments, occupancy and country shares are Eurostat; the regulation, its dates, its entries and its exemptions are the Official Journal, the Commission and the Council; the clinical capacity is Unither's own disclosure; the equipment envelope of 37,500 containers an hour is Rommelag's. No third-party market-sizing estimate is used anywhere in this report or in its arithmetic.
The honest summary is that this is a market report whose headline CAGR should not be quoted without the sentence that follows it. 3.93 per cent is the average of a pool growing at 6.5 per cent and a pool being legislated to zero, and the arithmetic of averaging them destroys the only information a reader needs.
Market overview
Europe's monodose packaging market is worth USD 1,337.3 million across 22.70 billion packs in 2025, and it is not one market. Two pools share the word and share nothing else, as our analysis of the sachet as a regulatory instrument sets out. Sterile clinical unit dose — ampoules and vials formed, filled and sealed in a single aseptic operation on a blow-fill-seal line — is 20.00 billion packs and USD 1,100.0 million of the total. Accommodation miniature packaging — the 30-millilitre shampoo bottle beside the sink — is 2.70 billion packs and USD 237.3 million. The first pool compounds on a clinical argument, and the arithmetic of the ten-to-one substitution is worked through separately. The second pool is removed from the European market on 1 January 2030 by Article 25 of Regulation (EU) 2025/40, whatever material it is made from.
| Pool | 2025 volume | Pack price | 2025 value | 2033 value | Direction |
|---|---|---|---|---|---|
| Sterile clinical unit dose (BFS ampoules, vials, unit-dose tubes) | 20.00 bn | USD 0.055 | USD 1,100.0 m | USD 1,820.5 m | +6.5% a year |
| Accommodation miniature packaging (mini-bottles, mini-tubes, wrapped soap) | 2.70 bn | USD 0.088 | USD 237.3 m | USD 0 | −100% by 2030 |
| Total | 22.70 bn | USD 0.0589 | USD 1,337.3 m | USD 1,820.5 m | +3.93% a year |
The aggregate is arithmetically correct and analytically useless. The market grows from USD 1,337.3 million to USD 1,820.5 million by 2033 — a 3.93 per cent value CAGR on a 4.83 per cent volume CAGR. Both figures are consistent with a market that is compounding. Neither describes what happens, because 100 per cent of the growth is clinical and 17.75 per cent of the 2025 value ceases to exist.
Value grows more slowly than volume for a physical reason rather than a pricing one. A miniature pack carries a price of USD 0.088 and a sterile unit dose USD 0.055, so the miniature is 1.60 times the pack price of the clinical unit. As 2.70 billion of the more expensive packs leave, the market's realised price per pack falls from USD 0.0589 to USD 0.0550. Europe will handle 45.8 per cent more packs in 2033 than in 2025 and bank 36.1 per cent more money, and the 9.7-point gap between those two figures is the miniature.
The physical base
The accommodation pool is not estimated. It is counted from Eurostat's accommodation statistics and then put through three stated parameters. The European Union recorded 3.14 billion nights in tourist accommodation in 2025, up 4.1 per cent on the 3.02 billion of 2024 — the first year the three-billion mark was crossed. Those nights were spent across more than 32 million bed places in roughly 680,000 establishments, with Italy (535 million nights), Spain (513 million), France (472 million) and Germany (440 million) accounting for more than six nights in ten. Average occupancy of bed places in hotels ran at about 50 per cent.
Dividing 3.14 billion nights by 1.9 guests per occupied room gives 1,652.6 million room-nights. At 3.4 monodose packs per room-night — shampoo, shower gel, soap and, on the upper tiers, conditioner and lotion — a fully miniature-served base would consume 5.62 billion packs. At the 48 per cent penetration the report models for 2025, that is 2.70 billion packs: 80.9 million litres of product moving through 2.70 billion discrete containers, or 84 packs a year for every bed place in the Union.
The clinical pool is built from disclosed capacity rather than from demand. Unither Pharmaceuticals, which describes itself as the world leader in sterile single doses, reports annual production capacity exceeding 5 billion doses across 14 blow-fill-seal lines and nine sites. The report assigns Unither 25 per cent of European sterile unit-dose output, which puts the European pool at 20.00 billion doses — 44.5 doses for every inhabitant of the Union. That 25 per cent is a Pheonix assumption, not a disclosed share, and the sensitivity chapter prices it.
Three cuts that sum to the total
Each cut below reconciles exactly to USD 1,337.3 million and 22.70 billion packs. The country cut is not allocated by judgement for the accommodation pool: it uses each country's measured share of EU nights.
By format
| Format | 2025 value (USD m) | Share | Volume (bn packs) |
|---|---|---|---|
| Blow-fill-seal ampoules and vials | 1,100.00 | 82.25% | 20.00 |
| Accommodation mini-bottles | 166.14 | 12.42% | 1.89 |
| Accommodation mini-tubes and wrapped soap sachets | 71.20 | 5.32% | 0.81 |
| Total | 1,337.34 | 100% | 22.70 |
By end use
| End use | 2025 value (USD m) | Share |
|---|---|---|
| Ophthalmic and preservative-free | 418.00 | 31.26% |
| Other sterile: ENT, respiratory, injectable, veterinary | 682.00 | 51.00% |
| Accommodation amenities | 237.34 | 17.75% |
| Total | 1,337.34 | 100% |
By country
| Country | 2025 value (USD m) | Share | Of which accommodation |
|---|---|---|---|
| Germany | 253.25 | 18.94% | 33.25 |
| France | 222.67 | 16.65% | 35.67 |
| Italy | 183.44 | 13.72% | 40.44 |
| Spain | 126.78 | 9.48% | 38.78 |
| Rest of EU-27 | 551.20 | 41.22% | 89.20 |
| Total | 1,337.34 | 100% | 237.34 |
What the report does not measure, and why
Single-portion condiment sachets in the HORECA channel are monodose in everything but name, are restricted by the same article of the same regulation in 2030, and are deliberately excluded from the sized market. No official series counts portions served, so any figure for them would be an artefact of an assumption rather than a measurement — and the assumption would dominate the total. The regulatory chapter treats them fully, because their legal treatment is identical to the hotel miniature's and their economics are not.
The second exclusion is multi-dose. A 300-millilitre pump bottle is not monodose under any reading, and the substitution the ban forces moves volume into precisely that format. The report measures what is banned and what replaces it in units and capital, not in packaging revenue, because the replacement pack is a different product sold through a different commercial relationship.
Table of Contents
Competitive Landscape
Competitive landscape
Two suppliers sit at the top of this market and neither of them sells against the other. Unither Pharmaceuticals holds the clinical end; ADA Cosmetics holds the amenity end; and Rommelag supplies the machine that makes the first pool possible while competing with the converters who run it. Concentration in a market described as one market is therefore meaningless: the two halves have different competitors, different customers and, from 2030, different regulatory weather.
The clinical end: one leader and its own disclosure
Unither describes itself as the world leader in sterile single doses, with annual production capacity exceeding 5 billion doses, 14 blow-fill-seal lines and nine sites, with operations in France, Brazil, the United States and China. On the report’s 25 per cent share assumption that is 25.0 per cent of a 20.00 billion dose European pool — a share that on its own sets a floor of 625 on the Herfindahl-Hirschman index before a single competitor is counted. Two suppliers at 10 per cent each would take the index past 800; the European market is moderately consolidated at the top and long in the tail, which is why tier1_player_count is set at two and not at one.
Unither’s two disclosures do not reconcile, and the gap is worth stating because the whole capacity argument rests on them. Five billion doses across 14 lines is 357 million doses per line-year. Running 8,760 hours, that requires 40,770 containers an hour per line — above the 37,500 that Rommelag quotes as the ceiling for its fastest bottelpack machines. At a realistic 6,000 operating hours the requirement is 59,524 an hour. Either the 14-line count excludes multi-machine lines, or the 5 billion doses are counted in a unit that is not one container — a strip or a card, for instance. The report takes the 5 billion as capacity and treats the line count as indicative. A reader who wants to challenge the sizing should challenge this, not the Eurostat base.
The equipment layer sits inside its own customer base
Rommelag invented blow-fill-seal and sells bottelpack machines that produce up to 37,500 BFS containers an hour; it also runs contract filling and development as a CDMO. That is a structurally unusual position — the machine supplier is also a competitor to the fillers who buy its machines — and it matters for the forecast, because incremental European clinical capacity can arrive either as a capital purchase or as outsourced volume, and Rommelag monetises both.
The amenity end: the dispenser was already in the catalogue
ADA Cosmetics, based in Kehl, Germany, sells across more than 50 countries and carries two product lines that matter for this report. The first is the miniatures themselves, including licensed and own brands across beauty, wellness and lifestyle ranges — the assets that made the miniature a marketing instrument rather than a toiletry. The second is a dispenser range: SmartCare, SmartCare Mini and SmartCare XL, SHAPE and SHAPE Mini, ILLI and press+wash, marketed on patented membrane technology that the company claims eliminates dripping, back contamination and wear-out, and on a hygienic pump described as shower-resistant with precise dosing.
That is the competitive fact the market report exists to explain. The supplier that loses 2.70 billion miniature packs does not lose the customer. It loses the pack, keeps the room, and sells a dispenser and a refill instead. The transition concentrates the amenity end rather than fragmenting it, because a dispenser installation is a multi-year fixture relationship with a service and restocking tail, and a buyer who has just been forced to make one capital decision is not minded to make it again on price.
What the exit of the miniature does to rivalry
The pool is 17.75 per cent of market value and 11.88 per cent of volume. Removing it does not create a vacuum: it removes the cheapest point of entry into hotel amenity supply, which was a branded 30-millilitre bottle. Entry after 2030 requires dispenser tooling, a refill filling line and a service network, and that is a materially higher wall. The regulation’s effect on competition is therefore the opposite of its effect on value: fewer participants, higher fixed costs, and a market that grows more slowly in money while becoming harder to enter.
Value Chain
Value chain
The two pools have opposite value chains and the difference is where the pack is made, not what it contains. In the clinical pool, blow-fill-seal collapses three steps into one: the polymer parison is extruded, blown into the mould, filled while still inside the mould and sealed in the same operation. There is no separate bottle supplier, no separate filling line and no open container at any point. In the amenity pool, the pack is made by a converter from a laminate or a moulded bottle, shipped to a filler, filled with product, and distributed through an amenity supplier to a hotel. The first chain has one asset. The second has four hand-offs.
The miniature’s economics, per occupied room-night
The report prices packaging, not product. At USD 0.088 a miniature and 3.4 packs per occupied room-night, a hotel buys USD 0.299 of packaging for every occupied room-night — roughly USD 109 a year for a room occupied 365 nights, and USD 54.6 at 50 per cent occupancy. Against that, the product inside those packs totals 102 millilitres a night. The miniature’s commercial genius and its regulatory vulnerability are the same fact: it delivers a very small quantity of product through a very large amount of surface.
| Step | Clinical BFS | Amenity miniature |
|---|---|---|
| Pack formed by | Same machine that fills it | Converter, separately |
| Container open to air | Never | From moulding to capping |
| Hand-offs before hotel | One (CDMO to brand) | Four (converter, filler, amenity supplier, distributor) |
| Price driver | Line time and validation | Laminate or resin, decoration, fill and freight |
| 2025 pack price | USD 0.055 | USD 0.088 |
What replaces a miniature, in units
A 300-millilitre refill contains ten times the product of a 30-millilitre miniature. So the substitution the ban forces is a ten-to-one collapse in pack count with no change at all in product volume: the 2.70 billion packs that carry 80.9 million litres become roughly 270 million refills carrying the same 80.9 million litres. Three consequences follow arithmetically. The converter loses 90 per cent of the units. That layer — film, board and thermoformed sheet — is sized in our global material and packaging coverage. The filler loses 90 per cent of the fill operations and gains a larger, lower-speed one. And the packaging value of the pool falls at any refill price below USD 0.88, which is ten times the miniature’s own pack price — because only at that price does a tenth of the packs carry the same value.
No refill is sold at ten times the pack price of a miniature. The pool’s value therefore falls, and it falls by more than half at any plausible ratio. That is the arithmetic argument that the accommodation monodose business is not migrating — it is being closed.
The five per cent mass test is a scope rule, not a safe harbour
Annex V entries 1 to 4 use the phrase “single-use plastic packaging”, and the Commission’s 2026 guidance resolves what that means: packaging containing more than 5 per cent plastic by mass, following the composite-packaging definition that disregards a material forming an insignificant part of the pack — the same composite definition that governs the thresholds in Europe’s PFAS-free food contact packaging market. A paper sachet with a plastic barrier above that threshold is single-use plastic packaging and is caught. At or below it, the pack is outside those entries altogether.
Packaging teams have read this as a design target — keep the plastic under 5 per cent and the pack is safe. It is not a design target; it is the test that decides whether the pack is assessed at all. And it is stated for entries 1 to 4 only. Entry 5, the hotel miniature, contains no material test and no threshold, which is why a coated-paper or aluminium miniature is as prohibited as a plastic one. Any substitution strategy that treats the 5 per cent rule as a route around the accommodation ban is answering a question the regulation does not ask.
Investment Activity
Investment analysis
The ban does not delete a market; it converts an annual consumable into a one-off capital cycle with a smaller consumable attached. That is the most useful single thing an investor can know about this pool, and it has a number: USD 237.3 million of annual packaging value leaves, and roughly 32 million dispensers have to be installed to serve the same rooms.
The dispenser count comes from the measured base. The European Union has more than 32 million bed places; at two beds per room that is about 16 million rooms, and at two dispensers per room — one at the basin, one in the shower — 32 million units. No part of that figure is a forecast: it is the stock that exists, multiplied by the fixtures a compliant room needs.
When the capital has to land
Article 25 bites on 1 January 2030 and Annex V entry 5 carries no derogation and no transition. From the regulation’s application date of 12 August 2026 to 31 December 2029 is three years and four months, and dispenser installation is renovation-coupled: nobody installs fixtures into a room they are not otherwise touching. The practical effect is that the majority of the stock has to be converted inside the final two renovation seasons, which is a procurement spike rather than a smooth curve, and it lands on a supplier base that is already consolidating around the transition.
What the clinical pool has to build
The clinical pool grows from 20.00 billion doses to 33.10 billion by 2033 — 13.10 billion additional doses. At Rommelag’s 37,500-an-hour envelope that is 39.9 machine-years of continuous running, or 58.2 machines at 6,000 hours a year. That is the capital requirement behind the forecast, and it is why the clinical growth rate is the load-bearing assumption in this report: 6.5 per cent a year is not a demand statement, it is a statement about how much blow-fill-seal capacity Europe is prepared to fund.
| 2025 | 2033 | Change | |
|---|---|---|---|
| Clinical doses | 20.00 bn | 33.10 bn | +13.10 bn |
| Machine-years at nameplate (continuous) | 60.9 | 100.8 | +39.9 |
| Machines at 6,000 hours a year | 88.9 | 147.1 | +58.2 |
| Accommodation packs | 2.70 bn | 0 | −2.70 bn |
| Dispensers required | — | 32 m | +32 m |
The replacement test an investor should run
Replacing the miniature pool’s value inside the clinical pool requires 4,315 million unit doses at USD 0.055 — 21.58 per cent more clinical volume than Europe fills in a single year. That is the cleanest way to see why the aggregate CAGR misleads. The clinical pool would have to grow by more than a fifth in one year simply to stand still in value after the ban, and it grows at 6.5 per cent. The market does not stand still: it loses a fifth of its value base and spends four years growing back through a different product.
The investment conclusion is therefore not “avoid packaging”. It is that the two pools require different capital and reward different owners. The clinical pool rewards whoever funds blow-fill-seal lines and validation. The accommodation transition rewards whoever owns the dispenser range and the refill filling relationship — and it punishes the converter whose press was amortised on miniature labels.
Two things the report cannot price
First, the working-capital swing: 2.70 billion small packs replaced by 270 million large ones changes inventory, freight and warehousing more than it changes revenue, and no disclosed figure exists for the hotel amenity channel’s stock. Second, the value of the brand licence inside the miniature. A co-branded 30-millilitre bottle is a marketing instrument, and marketing budgets do not appear in packaging statistics. Both are named here so that the gap is visible rather than assumed away.
Technology & Innovation
Technology and innovation
Blow-fill-seal is the only packaging technology in this market where the pack is never an open container. A polymer parison is extruded, blown to shape inside a closed mould, filled while still inside that mould, and sealed before the mould opens. The container is formed, filled and closed in one aseptic operation with no human intervention and no exposure to room air. Rommelag, which invented the process, quotes bottelpack machines producing up to 37,500 containers an hour.
The technology’s commercial consequence is not speed. It is that the pack can carry a formulation with no preservative, because nothing has had the opportunity to contaminate it. That is why the clinical pool grows: the pack does clinical work. A preservative-free eye drop exists because a unit dose exists, not the other way round.
| Attribute | BFS unit dose | Miniature bottle |
|---|---|---|
| Container opened during production | No | Yes — moulded, then filled |
| Preservative required in formula | No | Typically yes |
| Material system | Single polymer, one piece | Bottle, cap, label; often multi-material |
| Recyclability by 2030 requirement | Structurally easier — mono-material | Harder — label, cap and liner all count |
| Material test in Annex V | None (entry 5 does not use one) | None — banned regardless of material |
The capacity envelope and the arithmetic that tests it
Twenty billion doses is 60.9 machine-years at 37,500 an hour running continuously, or 88.9 machines at 6,000 hours a year. Those are the two numbers that make the European pool auditable: a reader who believes Europe has fewer than sixty large BFS machines running flat out should revise the dose count down, and a reader who believes it has many more should revise it up. The report’s 25 per cent share assumption for Unither is the only judgement in that chain.
The dispenser is a different engineering problem
The replacement technology is not a smaller or cleaner sachet. It is a fixed dispenser with a pump or a membrane. ADA Cosmetics markets two mechanisms: a patented membrane described as eliminating dripping, back contamination and the wear-out effect, and a hygienic pump described as shower-resistant with precise dosing. Both claims are engineering answers to the questions a hotel actually asks — will it drip on a tile, will it grow something between guests, will it survive being dropped in a shower.
Note what the membrane claim implies about the miniature’s real function. A disposable bottle does not need to survive anything; the dispenser must survive several years and a thousand actuations. The material intensity of the category therefore rises at the fixture and falls at the refill, and the compliance question moves from “is this pack recyclable” to “is this system serviceable”.
Where the design effort is actually going
Three directions, in order of consequence. Mono-material unit dose, because the 2030 recyclability requirement reaches every pack on the EU market and a one-piece polyolefin ampoule is the easiest object in packaging to make recyclable. Barrier without aluminium, for products that need oxygen protection but are caught by the composite rules. And the 5 per cent question, which for entries 1 to 4 has turned the mass of plastic in a paper pack into a design specification — a strange outcome for a sustainability law, and one that makes the material balance a line item in every development brief.
What is not being engineered is the miniature. No compliant version of it exists in the accommodation channel, because the prohibition is on the format and the use together, not on a material or a design. That is the difference between a design problem and a legal one, and it is why the innovation budget on the amenity side has moved entirely into dispensers and refills.
Market Risk
Market risks
Five risks matter, and they are ranked below by durability — how long each one persists rather than how large it is on the day it arrives. Two are structural and will outlast the forecast window; three are assumptions in this model and would change the number rather than the story.
| # | Risk | Durability | What it does to the number |
|---|---|---|---|
| 1 | Clinical growth carries 100 per cent of the forecast | Structural | One point of CAGR is USD 141.3 m on the 2033 pool — 7.76% |
| 2 | Unither’s share is an assumption, not a disclosure | Structural | At 20% the 2025 clinical pool is USD 1,375.0 m, not 1,100.0 |
| 3 | Enforcement and interpretation of Annex V entry 5 | Persistent | No derogation exists; a delay moves the cliff, not the drop |
| 4 | Substitution economics: the refill costs more per pack than the miniature | Cyclical | Falls entirely on hotel operating cost, not on pack value |
| 5 | Price erosion in unit dose | Cyclical | Held flat here; a 1 per cent fall is USD 33.1 m by 2033 |
Risk 1: the forecast is a single number wearing a market’s clothes
If the clinical pool grows at 7.5 per cent rather than 6.5, the 2033 market is USD 1,961.8 million instead of 1,820.5 — a difference of USD 141.3 million, or 7.76 per cent of the base case. At 5.0 per cent and a settled pack price of USD 0.052 it is USD 1,536.6 million. That is the honest shape of this report: a band from 1,536.6 to 2,147.1 around a base of 1,820.5, produced almost entirely by one growth rate.
Risk 2: the share assumption is worth more than any price assumption
Unither’s capacity is disclosed; its share is not. The report uses 25 per cent. At 20 per cent the European clinical pool is USD 1,375.0 million in 2025 — 275.0 million higher — and USD 2,275.6 million in 2033, 455.1 million higher. Nothing else in the model moves the total by that much, which is why the assumption is printed in the executive summary rather than in a footnote.
Risk 3: the cliff is legal, and law does not drift
Annex V entry 5 records no exemption text, and the Commission’s own public example of the restriction is a mini shampoo bottle in a hotel. Unlike entry 3, which Member States may soften for micro-enterprises, entry 5 offers no such discretion. The live uncertainty is interpretive rather than legislative: whether a large refill cartridge supplied per booking counts as accommodation packaging for an individual booking. A cartridge that stays in the room across bookings is a fixture and is outside the entry; a sealed cartridge handed to a guest is not. That line will be drawn in guidance and in litigation, and it is the only route by which any part of the 2.70 billion packs survives.
Risk 4: the ban moves cost, and cost is not a packaging statistic
At any refill price below ten times the miniature’s pack price, packaging value falls. But the hotel’s total amenity cost can rise anyway: it now buys fixtures, refills and a service relationship instead of a consumable delivered with the linen. That cost lands on operators in the middle of a renovation cycle, and it is the reason conversion will be late, lumpy and concentrated in the final two seasons before the deadline.
Risk 5: constant money is a convenience, not a forecast
The model holds pack prices flat from 2025 to 2033. Unit-dose prices are set by line time and validation rather than by resin, so they are stickier than most packaging prices, but a 1 per cent annual decline would take USD 33.1 million off the 2033 pool, and import competition from lower-cost blow-fill-seal capacity is a real route to it. A reader who expects price erosion should read the base case as the top of the range, not the middle of it.
Regulatory Landscape
Regulatory landscape
One article of one regulation decides this market, and it is unusually unambiguous. Regulation (EU) 2025/40 on packaging and packaging waste entered into force on 11 February 2025 and applies from 12 August 2026. Article 25(1) provides that from 1 January 2030 economic operators shall not place on the market packaging in the formats and for the uses listed in Annex V. There are six entries. Two of them are monodose.
| Entry | Format and use | Exemption |
|---|---|---|
| 1 | Single-use plastic grouped packaging | None recorded |
| 2 | Single-use plastic packaging for pre-packed fresh fruit and vegetables under 1.5 kg | Member State derogations on food-loss grounds |
| 3 | Single-use plastic packaging for food and drink filled and consumed on premises in HORECA | Premises without drinking water; micro-enterprises where a Member State allows |
| 4 | Single-use plastic packaging for condiments, preserves, sauces, coffee creamer, sugar and seasoning in HORECA | Take-away for immediate consumption; medical-care settings |
| 5 | Single-use accommodation sector packaging for an individual booking — shampoo and lotion bottles, sachets around bar soap | None recorded |
| 6 | Very lightweight plastic carrier bags below 15 microns | Hygiene and loose-food cases |
Entry 5 is the only entry that does not say “plastic”
The format column of entry 5 refers to single-use accommodation sector packaging without a material qualifier, and the Commission’s June 2026 guidance applies its 5 per cent plastic mass test to entries 1 to 4 only. The consequence is direct: a paper, aluminium or compostable miniature is as prohibited as a plastic one, because the prohibition attaches to the format and the use together. The frequently repeated claim that the law bans miniatures only above 50 millilitres, or only in plastic, is wrong on both counts — the threshold was in the 2024 proposal and was removed from the adopted text, and the material qualifier was never in this entry.
What is not banned
Fixed dispensers, wall-mounted pump formats and refillable systems remain lawful, and the Council’s own summary of the regulation describes the outcome as hotels using refillable containers for toiletries. Nothing in entry 5 prevents a sealed refill from being sold to a hotel; what it prevents is single-use packaging intended for an individual booking and discarded before the next guest. A refill that stays in the room across bookings is outside the entry’s scope — the line the market is currently drawing for itself.
The regulation does more than ban
The ban is the loudest instrument in a set that all press in the same direction for a small pack with a large surface. Packaging waste must fall 5 per cent by 2030, 10 per cent by 2035 and 15 per cent by 2040 against 2018, per capita, per Member State. All packaging on the EU market must be recyclable in an economically viable way by 2030. Grouped, transport and e-commerce packaging may not exceed 50 per cent empty space. At least 90 per cent of single-use plastic and metal beverage containers must be separately collected by 2029. Reuse targets bite on transport packaging at 40 per cent by 2030 and grouped packaging at 10 per cent. Extended producer responsibility fees are modulated by design, which converts every one of those obligations into a per-pack cost line.
For a monodose pack, each of these is a headwind and none is the reason the accommodation pool dies. The pack-to-product ratio is the wrong way round and its surface is usually multi-material, so it fails the recyclability test, the minimisation test and the fee modulation at the same time. The clinical pool is exposed to the same rules on the same date and passes them for a structural reason: a one-piece polyolefin ampoule is among the simplest objects in packaging to recycle, and its pack-to-product ratio is set by the dose, which cannot be reduced.
The asymmetry worth remembering
The same regulation that kills 2.70 billion packs protects 20.00 billion of them, because one dose exists to substitute for a preservative and the other exists to substitute for a bottle. Europe has not decided that monodose is waste. It has decided that a single dose is legitimate when the pack does clinical work and illegitimate when it does convenience work — and from 1 January 2030 the European market will contain only one of the two.